NASDAQ:NXTC - NextCure Stock Price, Forecast & News

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

NextCure Inc (NASDAQ:NXTC) announced its earnings results on Tuesday, November, 12th. The company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.02. The firm had revenue of $1.58 million for the quarter, compared to analyst estimates of $1.50 million. View NextCure's Earnings History.

NextCure is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for NextCure.

6 Wall Street analysts have issued 1-year target prices for NextCure's stock. Their forecasts range from $44.00 to $87.00. On average, they expect NextCure's stock price to reach $66.17 in the next year. This suggests a possible upside of 32.8% from the stock's current price. View Analyst Price Targets for NextCure.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NextCure.

Press coverage about NXTC stock has been trending very positive recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. NextCure earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for NextCure.

NextCure saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,040,000 shares, an increase of 120.1% from the December 15th total of 472,500 shares. Based on an average daily volume of 558,700 shares, the days-to-cover ratio is currently 1.9 days. Currently, 9.2% of the shares of the stock are short sold. View NextCure's Current Options Chain.

Some companies that are related to NextCure include BridgeBio Pharma (BBIO), Evotec (EVTCY), United Therapeutics (UTHR), Allakos (ALLK), Blueprint Medicines (BPMC), Nektar Therapeutics (NKTR), SAGE Therapeutics (SAGE), HUTCHISON CHINA/S (HCM), FibroGen (FGEN), Mirati Therapeutics (MRTX), GW Pharmaceuticals PLC- (GWPH), Deciphera Pharmaceuticals (DCPH), Ultragenyx Pharmaceutical (RARE), Myokardia (MYOK) and Intercept Pharmaceuticals (ICPT).

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include Alibaba Group (BABA), NVIDIA (NVDA), Honeywell International (HON), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Cisco Systems (CSCO), CVS Health (CVS), Home Depot (HD), Mcdonald's (MCD) and Procter & Gamble (PG).

(NXTC) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO.

NextCure's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Alpine Global Management LLC (0.06%). Company insiders that own NextCure stock include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan. View Institutional Ownership Trends for NextCure.

NXTC stock was bought by a variety of institutional investors in the last quarter, including Alpine Global Management LLC. Company insiders that have bought NextCure stock in the last two years include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan. View Insider Buying and Selling for NextCure.

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NXTC stock can currently be purchased for approximately $49.84.

NextCure has a market capitalization of $1.13 billion. View Additional Information About NextCure.

The official website for NextCure is http://www.nextcure.com/.

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]